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Increasing parity and duration of combined oral contraceptive (COC) use provide substantial protection against ovarian
carcinoma (cancer). There are limited data on the impact of the age of the births or age of COC use on reducing ovarian cancer
risk. Here, we examined the effects of age at first and last births and age at use of COCs using data from studies conducted
in Los Angeles County, California, USA (1,632 cases, 2,340 controls). After adjusting for the number of births, every 5 years
that a first birth was delayed reduced the risk of ovarian cancer by 13% (95% CI 5–21%; p50.003); a first birth after age 35
was associated with a 47% lower risk than a first birth before age 25. COC use before age 35 was associated with greater
protection per year of use than COC use at older ages. Considering previously published results as well as the results
presented here, increasing parity and a later age at births are both important protective factors against ovarian cancer and
the protection extends over 30 or more years from last birth. Current models of the etiology of ovarian cancer do not
encompass an effect of late age at births. Our result of an attenuation of the protective effect with COC use after around age
35 needs further investigation as it has not been seen in all studies.
Parity and combined oral contraceptive (COC) use provide
substantial protection against ovarian carcinoma (ovarian
cancer).1–9 The protection increases with an increasing num-
ber of births and with longer use of COCs,2,10 and the pro-
tection lasts for many decades after the last birth or after
stopping use of COCs.10 There is conflicting literature on the
impact of the age of the births on reducing ovarian cancer
risk,3–9 and little data on whether the age at which COCs are
used affects the degree of protection.10 The answer to the
question of whether age at births affects ovarian cancer risk
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has the potential of informing on the underlying mechanism
through which parity influences risk of ovarian cancer.
Whether age at COC use affects ovarian cancer risk is
important from a prevention perspective. Ideally use of COCs
for prevention purposes would be done at an earlier age to min-
imize the impact of the transient increased risk of breast cancer
associated with COC use11 given that the absolute risk of breast
cancer among young women is at its lowest level.
In this article, we have investigated the effects of ages at first
and last birth and ages at use of COCs on ovarian cancer risk
using data from four case-control studies of ovarian cancer
conducted in Los Angeles County (LAC), California during the
period 1992 through 2008.1,12 These studies used identical data
collection methods including a personal interview with each
participant using a life calendar detailing the timing of the
exposures of interest, including births and COC use, which
affords us the opportunity to look in detail at the timing of
these exposures. The results presented here are based on pool-
ing the questionnaire data from the four studies.
Material and Methods
We have previously published details of the methods used in
the four studies.1,12 These studies were approved by the Uni-
versity of Southern California (USC) Institutional Review
Board, and written informed consent was obtained from each
case and control before her interview.
Case ascertainment
For all studies, newly diagnosed histologically confirmed
ovarian cancer cases were identified from the Cancer Surveil-
lance Program (CSP) of the University of Southern Califor-
nia; the CSP is the Surveillance, Epidemiology and End
Results (SEER) Registry for LAC. Eligible patients were
female residents of LAC of self-reported non-Hispanic white,
Hispanic, or African-American race/ethnicity. Cases were eli-
gible for inclusion in the study if they were between 18 and
74 years of age at diagnosis and up to age 79 for cases diag-
nosed between 2003 and 2008. A total of 3,370 patients met
the study criteria. Overall, 15.7% of patients declined to be
interviewed, 16.9% had died or were too ill to be interviewed,
and 11.4% could not be located or had moved out of LAC.
We were thus able to carry out in-person interviews with
1,886, a 63.2% participation rate of the patients approached.
The response rate was higher for patients diagnosed with
localized cancer (69%) compared with those with more
advanced stage (61%). Response rates were highest for those
diagnosed under age 60 (70%), intermediate for those ages
60–69 (59%) and lowest for those ages 701 (47%). In this
analysis, we excluded 185 patients who had a previous cancer
(other than non-melanoma skin cancer) or had prior bilateral
oophorectomy, and a further 69 cases with missing or incon-
sistent data on one or more of the variables included in the
analysis presented here. The final analysis was based on
1,632 cases.
Control ascertainment
Controls were female residents of LAC with at least one
intact ovary identified using a well-tested control selection
algorithm.1 Briefly, we initially defined a specified sequence
of houses to be visited in the neighborhoods where index
cases lived at the time of diagnosis. We then sought to inter-
view the first eligible resident in the sequence. If the first eli-
gible control subject refused to participate, the second eligible
one in the sequence was asked, and so on. Letters were left
when no one was home, and follow-up was by mail and tele-
phone. Controls were individually matched to cases on neigh-
borhood, race/ethnicity and year of birth (65 years). In one
study, selection of controls for cases >65 years of age was
augmented, if necessary, by using lists of female residents of
LAC provided by the Health Care Financing Administration,
matched to the case on zip code, race/ethnicity and year of
birth closest to the case’s year of birth. We excluded potential
controls who had ever been diagnosed with a cancer (ignor-
ing non-melanoma skin cancer). Overall, 70% of the controls
interviewed were the first identified control.
Data collection
In-person interviews were conducted using a standardized
questionnaire that included the use of a life calendar. The
questionnaire covered events up to 12 months before a case’s
diagnosis date and a similar reference date for the controls.
The demographic, lifestyle and medical history variables
considered in this analysis include age, age at menarche, edu-
cation, SES (socio-economic status based on census tract of
residence),13 tubal ligation, self-reported physician-diagnosed
endometriosis, first-degree family history of ovarian cancer,
talc use, current body mass index (BMI, kg m22), COC use,
gravidity, parity, self-reported physician-diagnosed history of
infertility not attributable to problems of the partner and
tumor histology (from the SEER registry).
What’s new?
Parity and combined oral contraceptives (COCs) are associated with a lower risk of ovarian cancer. But might maternal age
also play a role? In this study, the authors found that a first birth at a later age provides significant additional protection
above that of parity alone. (A first birth after age 35 may provide more than double the protection of a birth before age 25.)
COC use before the age of 35 may also be associated with a greater protective benefit than use at older ages, but further
investigation is needed.
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Statistical analysis
We used stratified multivariate logistic regression, using the
statistical package program STATA 13 (StataCorp, College
Station, TX). At the termination of each study, some cases
had not been matched to a control and there were some con-
trols whose cases had to be excluded after they completed
the interview, because they were ineligible for the current
analysis (e.g., not ovarian cancer or did not live in LAC at
the time of diagnosis). Although the studies were designed as
matched case–control studies, in this report we have used
all interviewed cases and controls by adopting a stratified
multivariate logistic regression analysis approach with joint
stratification for the four studies, three race/ethnicity groups
and age groups (<30, 5-year age groups through age 79).
The following risk factors were adjusted for in all (stratified)
analyses: first-degree family history of ovarian cancer (mother
or sister), history of endometriosis, talc use, tubal ligation and
history of infertility; all of which were entered in the logistic
regression analysis as categorical binary (Yes/No) variables.
Age at menarche (continuous variable) and BMI (continuous
variable) were also adjusted for in all analyses. In addition,
education (<high school graduate, high school graduate, some
further training, college graduate); and five levels of SES were
also adjusted for as categorical variables in all analyses.
Age and type of menopause was also adjusted for in all anal-
yses as a categorical variable with categories: premenopausal,
hysterectomy (before menopause) at age <40 years and 40
years, natural menopause (age at last natural menstrual
period—LNMP) at age <45 years, 452, 502 and 551. For a
woman who started menopausal hormone therapy (HT) while
she was still having natural periods and did not have any natu-
ral periods after stopping this episode of HT, age at menopause
was taken to be the age at which the subject began this episode
of HT. If a woman had a natural menstrual period at least 3
months after stopping HT, this episode of use was not consid-
ered in defining her age at menopause and not considered to be
an episode of HT. If a woman had no natural menstrual periods
after stopping COCs (which were started before menopause),
her age at menopause was taken as the age at which she last
took a COC. The justification for this approach is given in Pike
et al.14
Each episode of HT use was categorized as estrogen alone
(ET), sequential estrogen-progestin (sEPT), continuous com-
bined estrogen-progestin (cEPT) or other. ET was defined as
use of estrogen alone for 20 days per ‘month’; sEPT as use
of estrogen for 20 days per month and number of progestin
days 60% of number of estrogen days; and cEPT as use of
estrogen for 20 days per month and number of progestin
days the same or greater than number of days of estrogen.
The above factors, taken together, are termed ‘the basic
factor set’ and are adjusted for in all analyses.
Number of births (defined as a pregnancy of >26 weeks,
counting from date of last menses) was analyzed categorically
(0, 1, 2, 3 and 41) as well as a continuous variable; age at
first birth was analyzed categorically (<20 years, 202, 252,
302 and 351) as well as a continuous variable with these
categories scored as 1, 2, 3, 4 and 5; and age at last birth was
analyzed categorically (<25 years, 25–29, 30–34, 35–39 and
401) as well as a continuous variable with these categories
scored as 1, 2, 3, 4 and 5. Number of incomplete pregnancies
(pregnancy of 26 weeks) was analyzed as a continuous
variable.
Duration of COC use was analyzed categorically (no use,
use for <5 years, 52, 102 and 151 years) as well as a continu-
ous variable. We also analyzed the ages at which COCs were
used (duration of use at ages <25, 25–34 and 351 years of
age). The estrogen component of COCs was considered high if
the dose of ethinyl estradiol was >35 mg or if the dose of mes-
tranol was >70 mg. The progestin component was considered
high if the dose was equivalent to 0.30 mg of D,L-norgestrel or
higher. This schema was the one used in the two previous
papers addressing the issue of COC dose.1,15 We also had six
women who reported use of a progestin-only oral contraceptive
and these women were included as COC users.
The histologic type and grade of the ovarian cancers were
obtained from the LAC SEER registry. The ovarian cancers
were categorized into high (poor/undifferentiated) grade
serous ovarian cancer (HGSOC), low grade serous (LGSOC),
endometrioid, clear cell, mucinous or not known (including
serous of unknown grade).
Odds ratios and corresponding 95% confidence intervals
(CIs) were calculated as estimates of the relative risks (RRs),
and are presented as RRs. All statistical significance values
(p values) quoted are two-sided.
Results
There were 1,632 cases and 2,340 controls available for analy-
sis. The race/ethnicity, age, education and income distribu-
tions of these cases and controls are shown in Supporting
Information Table 1. Similarly, the relative risks for the well-
established risk factors of family history of ovarian cancer,
history of endometriosis, talc use and BMI are available in
Supporting Information Table 2.
Table 1 shows the relative risks for age at first birth and
age at last birth fitted separately and together, adjusted for
the ‘basic factor set’ and number of births (continuous) and
duration of COC use (continuous at age <35 years and con-
tinuous at age 35 years—see below). When fitted separately,
age at first birth and age at last birth were both highly signif-
icantly related to ovarian cancer risk. However, when fitted
together, only age at first birth remained significant. Com-
pared to a first birth under age 25, a first birth after age 35
was associated with a 47% reduced risk of ovarian cancer
(RR5 0.53, 95% CI 0.32–0.88). Similar results were obtained
when we restricted the analysis to cases and controls who
had only one birth, and when we restricted the analysis to
cases and controls who had two births (data not shown).
The relative risks associated with increasing numbers of
births adjusted for the ‘basic factor set’ and duration of COC
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use (continuous at age <35 years and continuous at age 35
years—see below) are shown in Table 2. The relative risk asso-
ciated with a single birth was 31% lower than that associated
with nulliparity, much lower than one would expect based on a
linear model (on a logistic scale) of reduction in risk with each
birth (RR5 0.87). However, when fitted together with the effect
of age at first birth, this markedly larger effect of a single birth
was eliminated completely. This was due to the much greater
average age at first birth among women who only had one
birth: 46% of controls who only had one birth had the birth at
age 30 or later, while only 14% of controls who had more than
one birth had the first birth at age 30 or later.
The relative risks associated with the duration of use of
COCs are shown in Table 3. Each 5 years of use was associ-
ated with a 28% lower risk of ovarian cancer (p< 0.001).
There was a 34% reduction in risk associated with 5 years of
COC use before age 35, while 5 years of use after age 35 was
only associated with a 14% lower risk (p for difference in
effect, 0.019). There was little difference in the reduction in
risk from a fixed duration of COC use before age 25 (0.62,
95% CI 0.52–0.80) and such use at ages 25–34 (0.71, 95% CI
0.60–0.83). The decreased protective effect seen with use after
age 35 was consistently seen in all estrogen and progestin
‘potency’ formulations (data not shown).
Table 4 shows the relative risks for numbers of births and
age at first birth by histotype. Although the relative risks
show the same relationships with each histotype, the effects
are greater for endometrioid and clear cell ovarian cancers,
and the effect of age at first birth is weakest and not statisti-
cally significant for HGSOC. Table 4 also shows the relative
risks for duration of use of COCs overall and by age at use
by histotype. The relative risks show approximately the same
Table 1. Ages at first and last birth and risk of ovarian cancer
Cases
(n51,225)
Controls
(n51,833)
Fitted separately Fitted together
Variable Adjusted RR1 95% CI p Adjusted RR1 95% CI p
Age at first birth (years)
<20 276 315 1.00 1.00
20–24 526 650 0.99 0.82–1.19 1.00 0.82–1.22
25–29 271 489 0.76 0.62–0.93 0.75 0.58–0.98
30–34 108 248 0.71 0.54–0.93 0.66 0.46–0.94
351 44 131 0.57 0.39–0.84 0.53 0.32–0.88
Per category 0.87 0.82–0.93 <0.001 0.87 0.79–0.95 0.003
Age at last birth (years)
<25 290 303 1.00 1.00
25–29 373 521 0.77 0.63–0.95 0.94 0.73–1.21
30–34 346 569 0.78 0.63–0.97 1.07 0.79–1.45
35–39 175 335 0.75 0.57–0.97 1.16 0.79–1.69
401 41 105 0.53 0.34–0.83 0.84 0.49–1.43
Per category 0.90 0.83–0.97 0.005 1.01 0.91–1.12 0.88
1Stratified analysis (see Methods) and adjusted for the basic factor set (family history of ovarian cancer, history of endometriosis, talc use, tubal ligation,
infertility, number of incomplete pregnancies, age at menarche, BMI, education, SES, age and type of menopause, type and duration of menopausal
hormone therapy) plus number of births (continuous) and duration of COC use at ages <35 years (continuous) and 351 yrs (continuous).
Table 2. Births and risk of ovarian cancer
Variable Cases Controls Adjusted RR1 95% CI p Adjusted RR2 95% CI p
Births
0 407 507 1.00 1.00
1 225 370 0.69 0.55–0.87 1.00 0.74–1.34
2 444 674 0.67 0.54–0.81 0.89 0.69–1.14
3 314 416 0.66 0.53–0.84 0.83 0.64–1.07
41 242 373 0.40 0.31–0.52 0.48 0.37–0.63
Per birth 0.86 0.82–0.90 <0.001 0.87 0.83–0.92 <0.001
1Stratified analysis (see Methods) and adjusted for the basic factor set (see footnote to Table 1), plus duration of COC use at ages<35 years (continuous)
and 351 yrs (continuous).
2As for footnote (1) plus age at first birth category (continuous).
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relationships with each tumor type, with the possible excep-
tion of clear cell ovarian cancers for which COC use in both
age groups was equally protective.
The relative risks associated with numbers of births, age
at first birth and duration of COC use by age at diagnosis is
shown in Table 5. Overall there was a 13% reduction in ovar-
ian cancer risk per birth. The reduction in risk per birth was
much stronger at younger ages at diagnosis: a 27% reduction
per birth at diagnosis ages <45 years compared to an
8% reduction at diagnosis ages 65 years. A similar trend
was observed for age at first birth with a 16% reduction at
diagnosis ages <45 years compared to a 9% reduction at ages
65 years (Table 5). No clear effect of age at diagnosis was
seen with the reductions in risk with COC use.
Discussion
Parity and COC use are well-established protective factors for
ovarian cancer, but as we move toward a model of personalized
prevention it is increasingly important to gain a more in-depth
understanding of these and other lifestyle factors associated
with risk. In the analysis presented here, the timing of both par-
ity and COC use influence the protection against ovarian can-
cer afforded by these exposures; a later age at first birth and an
earlier age at COC use provide greater benefit.
The reduction in risk we observed with increasing parity, a
relative risk of 0.87 per birth, is in good agreement with the
results of previous studies.3–9 We found an overall reduction in
relative risk of ovarian cancer of 0.87 per 5 years later age at
first birth. One possible explanation for this protective effect of
a late first birth that we observed is that the underlying reason
for a late age is related to a woman’s underlying ovarian cancer
risk. We examined the characteristics, including a history of
infertility, endometriosis and SES, of the women who had late
births and could not find a compelling explanation. If the
underlying mechanism of the protective effect of a birth is to
reduce cell proliferation one would expect that age at the birth
Table 3. Oral contraceptive (COC) use and risk of ovarian cancer
Variable Cases Controls Adjusted RR1 95% CI p
COC use (yrs)
0 707 734 1.00
>02 617 826 0.98 0.82–1.15
52 172 384 0.57 0.45–0.72
102 93 231 0.49 0.37–0.65
151 43 165 0.29 0.20–0.43
Per 5 yrs use 0.72 0.67–0.77 <0.001
Per 5 yrs use
<35 yrs of age 0.66 0.59–0.73
351 yrs of age 0.86 0.73–1.01
Difference test 0.019
1Stratified analysis (see Methods) and adjusted for the basic factor set (see footnote to Table 1), plus number of births (continuous) and age at first
birth category (continuous).
Table 4. Relative risks (95% CIs) for births, age at first birth (per 5 years category) and oral contraceptive (COC) use (5 years of use) and risk
of ovarian cancer, by histotype1
No. of cases Births, per birth2,3 Age at first birth2,3 COC use2,4
COC use <35
yrs2,4
COC use 351
yrs2,4
All women1 (n51,632) 0.87 (0.83–0.92) 0.87 (0.82–0.93) 0.72 (0.67–0.77) 0.66 (0.59–0.73) 0.86 (0.73–1.01)
HGSOC2 (n5559) 0.89 (0.83–0.96) 0.94 (0.86–1.04) 0.72 (0.64–0.80) 0.67 (0.57–0.79) 0.80 (0.63–1.02)
LGSOC2 (n5207) 0.93 (0.84–1.04) 0.87 (0.75–1.01) 0.69 (0.57–0.83) 0.65 (0.51–0.84) 0.78 (0.51–1.21)
Endometroid (n5192) 0.83 (0.74–0.93) 0.82 (0.70–0.95) 0.69 (0.58–0.83) 0.62 (0.49–0.79) 0.88 (0.60–1.29)
Clear Cell (n587) 0.72 (0.58–0.88) 0.74 (0.57–0.96) 0.64 (0.49–0.84) 0.66 (0.46–0.93) 0.61 (0.30–1.25)
Mucinous (n5119) 0.82 (0.71–0.96) 0.89 (0.74–1.08) 0.79 (0.64–0.98) 0.73 (0.54–0.97) 0.98 (0.60–1.60)
1Numbers do not sum to total due to missing histotype.
2Stratified analysis (see Methods) and adjusted for the basic factor set (see footnote to Table 1).
3Also adjusted for duration of COC use at ages <35 years (continuous) and 351 yrs (continuous).
4Also adjusted for number of births (continuous) and age at first birth category (continuous).
Abbreviations: HGSOC, high grade serous ovarian cancer; LGSOC, low grade serous ovarian cancer.
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would have no effect.16 If a birth results in a reduction of a stem
cell pool, an early age at birth should provide greater protec-
tion, as is seen in breast cancer.16 None of these explanations
seems to fit with our finding.
Previous studies on the effect of age at first and last births
showed associations with late age at both first and last
births.3–9 We also found a reduction in risk with increasing
age at last birth—relative risk of 0.90 per 5 years later. Five
Table 5. Analysis of births, oral contraceptive (COC) use and age at first birth and risk of ovarian cancer, by age at diagnosis
RRs and 95% CIs1
Age group Cases Controls Births2 Age at 1st birth3 COC <354 COC 3514
All ages 1,632 2,340 0.87 0.87 0.66 0.86
(0.83–0.92) (0.82–0.93) (0.59–0.73) (0.73–1.01)
<45 yrs 217 525 0.73 0.84 0.66 1.03
(0.61–0.87) (0.70–1.00) (0.52–0.84) (0.52–2.03)
45–54 yrs 470 776 0.86 0.87 0.59 0.77
(0.78–0.95) (0.77–0.97) (0.50–0.70) (0.56–1.07)
55–64 yrs 511 595 0.89 0.89 0.74 0.82
(0.82–0.97) (0.79–1.00) (0.61–0.90) (0.62–1.09)
651 yrs 434 444 0.92 0.91 0.69 0.86
(0.84–1.00) (0.78–1.06) (0.46–1.03) (0.64–1.14)
1Stratified analysis (see Methods) and adjusted for the basic factor set (see footnote to Table 1), plus duration of COC use at ages<35 years (continuous)
and 351 yrs (continuous).
2Relative risk (RR) per birth.
3RR per 5 years increase in age at first birth (see Table 1).
4RR per 5 years of use.
Table 6. Published results on effect of age at first and last births on risk of ovarian cancer1
Independent2
Reference Study type Cases Controls First Birth Last Birth
Whittemore et al.
(1992)9
Case-control 1,363 5,609 0.883
(0.80–0.96)
Adami et al.
(1994)3
Nested case-control 2,992 14,960 0.89
(0.84–0.94)
Titus-Ernstoff et al.
(2001)7
Case-control 563 523 0.883
(0.76–1.03)
0.893
(0.77–1.03)
Riman et al.
(2002)6
Case-control 655 3,899 0.973
(0.87–1.08)
“No association”
Whiteman et al.
(2003)8
Case-control 602 723 0.873
(0.75–1.01)
0.793
(0.69–0.91)
Moorman et al.
(2008)5
Case-control 713 838 0.873,4
(0.77–0.99)
0.813,4
(0.73–0.90)
Bevier et al.
(2011)4
Cohort 17,190 5.73106 0.963
(0.94–0.97)
0.903
(0.89–0.92)
1Excluding hospital-based studies.
2Relative risk (RR) per 5 years increase in age at first (last) birth, adjusted for parity (all studies).
3RR estimated from the published paper by the method of Greenland and Longnecker.17
4Combining results from premenopausal and postmenopausal women (see Table 6 of Moorman). These results are only given for invasive and
low-malignant potential cases combined, and it is not clear whether the results from first and last births are mutually adjusted. Their results are
stated in terms of pregnancies rather than births, but the numbers in their tables are for births.
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of the studies shown in Table 6 also reported on the associa-
tion of ovarian cancer risk with age at last birth.4–8 In three
of them,4,5,8 the reduced risk with age at last birth was clearly
greater than the reduction in risk with first birth. We found
that the effect of age at last birth was eliminated after adjust-
ment for age at first birth (Table 1), but Whiteman et al.8
found the reverse.
Considering the results of all the studies of birth timing
shown in Table 6 together with the results we found, we can
conclude that a late birth has a clear additional protective
effect against ovarian cancer over and above the protective
effect of number of births. If a birth results in a reduction of
precursor lesions, a late age at birth would provide greater
protection, as is seen in endometrial cancer.18
We found that the protective effects of parity and late age
at first birth diminished with increasing age at diagnosis
(Table 5). This reduction in protection with increasing age at
diagnosis has been consistently found in previous studies,
although these studies expressed this in terms of increased
time since first/last birth. Age at diagnosis and time since
first/last birth are, of course, positively correlated, and in our
data the results were much clearer when expressed in terms
of age at birth and age at diagnosis. The attenuation over
time is readily explained by models based on ovulatory years;
the years pregnant as a proportion of ovulatory years plus
time since menopause is reduced with increasing age,16 but
as Adami et al.3 pointed out, the effect of age at births can-
not be readily explained on the basis of models of incessant
ovulation or ovulatory years.
The important conclusion to be drawn from the results,
when all studies are considered together, is that parity and
age at births are both important protective factors and that
the protection extends over 30 or more years.
We found, as has been repeatedly found before,10 a clear
protective effect of COC use against ovarian cancer. The sur-
prising aspect of our finding is that earlier age at use of
COCs is associated with greater protection. We investigated
whether this was driven by temporal changes in the doses of
COCs, with early age at use potentially being associated with
higher dose COCs, but this was not the case. This finding
has important implications with respect to risk reduction
given that using COCs at a young age as a preventive strat-
egy is appealing given that the absolute risk of breast cancer
at a young age is low. Thus, the transient increased risk of
breast cancer associated with COC use11 would be less of a
concern.
It is important to note, however, that in The Collabora-
tive Group on Epidemiological Studies of Ovarian Cancer
major overview of epidemiological results on ovarian cancer
and COC use,10 no “index of timing of use . . . had any
material effect” on the reduction in risk of ovarian cancer
with COC use, so our finding of an attenuation of protective
effect with COC use after around age 35 should be regarded
as tentative and needs further investigation in other data
sets.
Overall, it appears that the age at births has an effect on
the degree of protection afforded by parity. Achieving a bet-
ter understanding of the effect of births on endometriotic
lesions, as the site of origin of endometrioid and clear cell
ovarian cancers, and on the fallopian tube as the major site
of HGSOC are needed to provide the information needed to
develop prevention strategies based on this finding.
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